Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balaglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 9/20 | 0.98 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.66 |
| ▸ | PPARA | Q07869 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ESRRA | P11474 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balaglitazone SCHEMBL20125575 | 0.99 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL242011 | 0.99 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL29362039 | 0.99 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL20125574 | 0.99 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL2567779 | 0.98 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935613 | 0.98 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL6359086 | 0.98 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935616 | 0.98 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| SCHEMBL5844579 | 0.88 | PPARG (0.80) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL1130955 | 0.87 | PPARG (0.79) | PPARGFFAR1PPARAESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377950-B2 | Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | claimed |
| EP-1623984-B1 | Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl] thiazolidine-2,4-dione potassium salt | REDDYS LAB LTD DR (IN) | 2011-11-02 | — | — | EP | claimed |
| EP-1623984-A1 | Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | Dr. Reddy's Laboratories Limited (IN) | 2006-02-08 | — | — | EP | claimed |
| US-20050234079-A1 | Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-10-20 | — | — | US | claimed |
| JP-2005523300-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S LABORATORIES LIMITED | 2005-02-10 | — | — | US | claimed |
| EP-1487830-A1 | NOVEL CRYSTALLINE FORM OF 5-(4-((3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)METHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE POTASSIUM SALT | Dr. Reddy's Laboratories Ltd. (IN) | 2004-12-22 | — | — | EP | claimed |
| WO-2003078425-A1 | NOVEL CRYSTALLINE FORM OF 5-[4-[[3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL]METHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE POTASSIUM SALT | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-09-25 | — | — | WO | claimed |
| US-8377950-B2 | Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| US-8377950-B2 | Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| US-8377950-B2 | Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| EP-1623984-B1 | Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl] thiazolidine-2,4-dione potassium salt | REDDYS LAB LTD DR (IN) | 2011-11-02 | — | — | EP | disclosed |
| JP-2010248246-A | NEW CRYSTALLINE FORM OF POTASSIUM 5-[4-[[3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL]METHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE | DR REDDYS LAB LTD | 2010-11-04 | — | — | JP | disclosed |
| JP-2010248246-A | NEW CRYSTALLINE FORM OF POTASSIUM 5-[4-[[3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL]METHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE | DR REDDYS LAB LTD | 2010-11-04 | — | — | JP | disclosed |
| US-6469167-B1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-(4-((3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)METHOXY)BENZYL) THIAZOLIDINE-2,4-DIONE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-10-22 | — | — | US | disclosed |
| US-20020010187-A1 | Pharmaceutical composition and the process for its preparation | NOVO NORDISK A/S (DK) | 2002-01-24 | — | — | US | disclosed |
| WO-2001091751-A1 | NEW PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS PREPARATION | NOVO NORDISK A/S (DK) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001089523-A1 | NEW PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS PREPARATION | NOVO NORDISK A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
| EP-1114047-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015638-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010187-A1 | Pharmaceutical composition and the process for its preparation | CYP3A5, CYP2C19, CYP3A4 | PPARG 966/4885FFAR1 3795/4885PPARA 1774/4885 |
| US-20050234079-A1 | Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt | SLC5A2, SLC5A1, KCNK5 | PPARG 1366/4885FFAR1 599/4885PPARA 1079/4885 |
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B2 | PPARG 380/4885FFAR1 1350/4885PPARA 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.